| David George Short, DO | |
|
1025 Michigan Avenue, Suite 215, Logansport, IN 46947-1594 | |
| (574) 753-2222 | |
| (574) 753-0522 |
| Full Name | David George Short |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 38 Years |
| Location | 1025 Michigan Avenue, Logansport, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134184153 | NPI | - | NPPES |
| 265973 | Other | IN | HARMONY |
| 000000090844 | Other | IN | ANTHEM |
| 000000596741 | Other | IN | ANTHEM (LMH) |
| 5231880002 | Other | IN | CIGNA |
| 1019948 | Other | IN | TRICARE |
| 0004358987 | Other | IN | AETNA |
| 100071010 | Medicaid | IN | |
| 356001853017 | Other | IN | TRICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital | Logansport, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hospital | 8123923281 | 73 |
News Archive
Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.
Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp., a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.
A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Hand washing among healthcare staff working in a large urban hospital improved by an average of 32 per cent after a six-week hygiene programme, according to a paper in the latest Journal of Advanced Nursing.
› Verified 6 days ago
| Entity Name | Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942317656 PECOS PAC ID: 8123923281 Enrollment ID: O20031206000001 |
News Archive
Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.
Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp., a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.
A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Hand washing among healthcare staff working in a large urban hospital improved by an average of 32 per cent after a six-week hygiene programme, according to a paper in the latest Journal of Advanced Nursing.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David George Short, DO 1025 Michigan Avenue, Suite 215, Logansport, IN 46947-1594 Ph: (574) 753-2222 | David George Short, DO 1025 Michigan Avenue, Suite 215, Logansport, IN 46947-1594 Ph: (574) 753-2222 |
News Archive
Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.
Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp., a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.
A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Hand washing among healthcare staff working in a large urban hospital improved by an average of 32 per cent after a six-week hygiene programme, according to a paper in the latest Journal of Advanced Nursing.
› Verified 6 days ago